Literature DB >> 18440312

Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.

Benoit You1, Paul Perrin, Gilles Freyer, Alain Ruffion, Brigitte Tranchand, Emilie Hénin, Philippe Paparel, Benjamin Ribba, Marian Devonec, Claire Falandry, Cécile Fournel, Michel Tod, Pascal Girard.   

Abstract

OBJECTIVES: A population kinetic approach based on PSA clearance (CL(PSA)) may be a more rational strategy to characterize prostate-specific antigen (PSA) decrease profile after prostate surgery than the commonly used method (half-life from mono/bi-exponential models).
METHODS: We used 182 post-adenomectomy PSA concentrations from 56 benign prostatic hyperplasia patients to build, with NONMEM software, a multi-exponential and a CL(PSA) model for comparison.
RESULTS: The best multi-exponential model was PSA(t)=4.96e(-)(0.269t)+3.10e(-)(0.16t)+0.746e(+)(0.0002t) with a stable median residual PSA at 0.64 ng/mL. The best model parametrized with clearance was CL(PSA)=0.0229()(AGE/69)(3.78). Akaike information criteria and standard errors favored the CL(PSA) model. Median peripheral zone and transitional zone productions were 0.034 ng/mL/cm(3) and 0.136 ng/mL/g. A threshold at 2 ng/mL on day 90 allowed for a diagnostic of biochemical relapse diagnostic.
CONCLUSIONS: The population CL(PSA) model was superior to the multi-exponential approach for investigating individual post-adenomectomy PSA decreases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440312     DOI: 10.1016/j.clinbiochem.2008.04.001

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling.

Authors:  David Ternant; Fabrice Ivanes; Fabrice Prunier; Nathan Mewton; Theodora Bejan-Angoulvant; Gilles Paintaud; Michel Ovize; Denis Angoulvant
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

2.  Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.

Authors:  Aurore Carrot; Reza-Thierry Elaidi; Olivier Colomban; Denis Maillet; Michel Tod; Benoit You; Stéphane Oudard
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

3.  Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.

Authors:  Marta Mendiola; Jorge Barriuso; Andrés Redondo; Adrián Mariño-Enríquez; Rosario Madero; Enrique Espinosa; Juan Angel Fresno Vara; Iker Sánchez-Navarro; Ginés Hernández-Cortes; Pilar Zamora; Elia Pérez-Fernández; María Miguel-Martín; Asunción Suárez; José Palacios; Manuel González-Barón; David Hardisson
Journal:  PLoS One       Date:  2008-12-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.